Chloro-4-phenyl thiomethylene bisphosphonate (tiludronate) is a new drug which can be used as an inhibitor of bone resorption. As it remains in bone for a long time, and as mineralisation defects have only been seen at doses much higher than those required to decrease osteoclastic activity, it could be given at high doses over a short period of time.
Abstract
Chloro-4-phenyl thiomethylene bisphosphonate (tiludronate) is a new drug which can be used as an inhibitor of bone resorption. As it remains in bone for a long time, and as mineralisation defects have only been seen at doses much higher than those required to decrease osteoclastic activity, it could be given at high doses over a short period of time.
Eighteen patients with Paget's disease of bone were randomly allocated to three therapeutic groups receiving respectively 600, 800, and 1200 mg/day tiludronate for five days. Serum alkaline phosphatase activity and the urinary hydroxyproline/creatinine ratio were quickly and drastically reduced in all three groups. A significant reduction of serum alkaline phosphatases and the hydroxyproline/ creatinine ratio was still present six months after the five day therapeutic course, reflecting a sustained activity of tiludronate even after stopping treatment. Dose dependent short and long term reductions of bone turnover rate were observed.
Biochemical assessment of haematological, renal, or hepatic tolerance did not show any toxicity of tiludronate. Fifty per cent of patients treated by a dose of 1200 mg/day reported gastrointestinal disturbances, however, making this dosage unsuitable for clinical practice. shown that treatment of Paget's disease of bone with short term courses of bisphosphonate may induce a sustained therapeutic effect. 7 We therefore, investigated the effect of three doses of tiludronate given by mouth for five days to patients with Paget's disease of bone.
Patients and methods Eighteen patients presenting radiological and scintigraphic evidence of Paget's disease of bone in one (three patients) or more (15 patients) bones were included in this study after informed consent (table). All patients had active Paget's disease as judged by increased serum activity of alkaline phosphatases and urinary excretion of hydroxyproline. Before this study, 10 patients had never been treated for Paget's disease of bone, salmon calcitonin had been used to treat five patients (dose ranging from 50 IU intramuscularly three times a week to 200 IU/day nasally for three to six months), hydroxyethylidene bisphosphonate had been used for four patients (5 mg/kg/day for six months), and one patient had received aminohydroxypropylidene bisphosphonate (250 mg/kg/day for six weeks). None of the patients had shown a normal value of serum alkaline phosphatases during previous treatments. A washout period of six months for calcitonin, three years for hydroxyethylidene bisphosphonate, and five years for aminohydroxypropylidene was respected before inclusion in the present study. All patients had relapsed as judged by a progressive increase in serum alkaline phosphatases of at least 20% from the lowest values reached with previous treatment.
Serum alkaline phosphatases were assessed by the method of Trayser and Seligson"4 (normal range 40-135 IU/1). After an overnight fast and voiding the bladder, the urine produced over a two hour period was collected for measurement of hydroxyproline (Kit Hypronostikon Teknika, Organon, Oss-Boxtel, The Netherlands). The hydroxyproline concentration was expressed as a ratio to creatinine excretion'5 (normal range 0-24 mg/g).
Patients were randomly assigned to three therapeutic groups, each containing six patients They were treated for five consecutive days receiving respectively 600 mg/day (Gr600), 800 mg/day (Gr800), and 1200 mg/day (Grl200) tiludronate by mouth. In the present study, we used a new formulation of tiludronate with a bioavailability twice as high (4-8% of the ingested dose) than that used in our previous studies,'3 16 for which the estimated bioavailability of tiludronate was between 2 and 4% of the ingested dose. Tiludronate was taken two hours before and after any food ingestion and only with 200 ml of deionised water (Spa Reine). Serum alkaline phosphatases and the hydroxyproline/creatinine ratio were assessed before the first intake of tiludronate (day 1) and on each subsequent day of treatment (days 2, 3, 4, and 5). These parameters were also measured after the discontinuation oftiludronate at two (day 14), three (day 21) , four (day 28), eight (day 56), 13 (day 90), 17 (day 120), 21 (table) .
At the beginning of the study there was no statistically significant difference between levels of serum alkaline phosphatases in the three groups. This allows us to compare changes in serum alkaline phosphatases in the three therapeutic groups during the study. This was not so for the hydroxyproline/creatinine ratio, which was significantly higher in Grl200 patients compared with the Gr600 group. Levels of serum alkaline phosphatases were significantly reduced (p<0 01) after two days of treatment in Gr600 (mean (SEM) -7-8(2-3)%), after four days in Gr800 (-29-3(13-8)%), and after one day in Grl200 (-13-1(4-4)%) . The maximum decrease in serum alkaline phosphatases was obtained at day 90 in Gr600 (-30-6(8-2)%), at day 90 in Gr800 (-45-8(9-3)%), and at day 120 in Grl200 (- 57-8(3-3%) ). At the end of the follow up (day 180), levels of serum alkaline phosphatases were still reduced in the three groups: -25-3(8-7)% in Gr600 (p<005), -3510(17-5)% in Gr800 (NS), and -57-6(4-1)% in Grl200 (p<0-02) (fig 1) . Gr800 following an intermediate dependent pattern. Indeed, the maximum n. The hydroxyproline/creatinine ratio decrease in serum alkaline phosphatases and the so quickly and drastically reduced in the reduction of this parameter reported at the end therapeutic groups: Gr600 -7 7(2 3)% of the six month follow up are almost twice two days (p<0 02) with a maximum as high in patients treated with 1200 mg/day se of -35-4(6-2)% at day 90 (p<0 01); tiludronate (-57-8(3-3)%; -57-6(4-1)%) than -29-3(13-8)% (p<005) after four days in subjects who received 600 mg/day (-30-6 a maximum decrease of -40-2(11-4)% (8 2)%; -25-3(8-7)%), whereas patients with 01) at day 90; and Grl200 -13-1(4-5)% Paget's disease treated by a daily dose of 800 mg 02) after one day with a maximum follow an intermediate pattern (-45-8(9 3)%; Lse of -40-2(12-0)% (p<0O01) at day 150 -35-0(175)%). At the end of the study, the decrease in Even with the higher dose of tiludronate, ydroxyproline/creatinine ratio was still however, the percentage of patients with significant in Gr600 (-17-9(6-5)%) complete and sustained biochemical remission D2) and in Grl200 (-33-6(12-2)%) remains low compared with those treated with )2) whereas in Gr800 the decrease in the other bisphosphonates such as aminohydroxy-,yproline/creatinine ratio did not reach propylidene, dichloromethylene bisphosphoical significance (-29-9 (19-9)%) (NS). nate, and aminohexane bisphosphonateS 18 19 the six month follow up period, only one by mouth for either a short or long period of t (7%) presented a complete biochemical time. The mean decrease of serum alkaline ion, assessed by a normalisation of serum phosphatases and the hydroxyproline/creatinine te phosphatases and the hydroxyproline/ ratio reported with tiludronate is relatively close line ratio, whereas five (33%) other to that obtained during treatment with calcitonin ts showed levels of serum alkaline or hydroxyethylidene bisphosphonate.' The iatases or a hydroxyproline/creatinine absence of fractures in lytic areas of weightwithin the normal range at that time bearing bones and the absence of an increase in bone pain in the same areas, as described for significant alteration of biochemical hydroxyethylidene bisphosphonate during treateters reflecting haematological, renal, or ment, might be considered as a relative indication c metabolism were recorded. Clinically, of the absence of impairment of mineralisation onate was perfectly tolerated in Gr800 when using these doses of tiludronate.' Ls, whereas one of six patients (16%) in No limiting side effects occurred in patients and three of six patients (50%) in Grl200 in Gr600 and Gr800. In Grl200, however, In conclusion, treatment with tiludronate by mouth at high doses for only five days is followed by a clinical and biochemical response which is sustained for several months. There is a dose dependent reduction of bone turnover rate. Gastrointestinal disturbances, however, make 1200 mg/day an unsuitable dose for clinical daily practice. The biochemical reduction of disease activity, persisting for months after the end of treatment, confirms the potential usefulness of tiludronate by mouth as an intermittent treatment for metabolic bone disorders characterised by an excess of bone resorption.
